Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland Abstract #2746

Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.
Aim(s): We aim to define new immunohistochemical markers expressed by specific GEP-NET subgroups with prognostic or predictive value and potential new therapy targets.
Materials and methods: At the ENETS CoE Zurich tissue microarray (TMA) blocks were constructed with 147 tissue samples of tumors diagnosed from 2000 to 2017, including primary tumors and metastasis. Tissue microarray sections were immunostained for SOX-9, SOX-10, SSTR-2 +, PDL-1, thyroid transcription factor 1 (TTF1), estrogen receptor-α (ER-α) and -β (ER-β), progesterone receptor (PR), androgen receptor (AR), BRAF and HER2.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr.med. Alexander Siebenhüner

To read results and conclusion, please login ...

Further abstracts you may be interested in

#435 Olfactory Receptor 51E1 is a Novel Potential Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (SI-NETs) get late diagnosis. We discovered the olfactory receptor 51E1 (OR51E1) as a potential target to develop as a novel biomarker.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Tao Cui
Authors: Cui T, Ryberg U, Li S C, Cunningham J, ...
#583 Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get late diagnosis. We reported olfactory receptor 51E1 (OR51E1) as a SI-NET-mRNA marker.
Conference:
Category: Basic
Presenting Author: Mr TAO CUI
#1483 Biomarker and Target Identification in GEP-NET: From in Silico Prediction to Validation on Patient Tissues
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors. Somatostatin agonist treatment has a key role in the management of GEP-NET. However, the prognosis of these tumors varies between individuals. There is, therefore, a need to identify novel prognostic and predictive biomarkers of therapeutic efficacy, as well as to propose novel therapeutic strategies.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Pascale Plas
Keywords: GPCR, miR
#2116 Ghrelin O-Acyltransferase (GOAT) Enzyme and Ghrelin Receptor GHSR1a as Putative Prognosis Markers and Therapeutic Targets in Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Specific components of ghrelin-system are associated with tumor development/ progression. We have previously described the presence of this system in neuroendocrine tumors (NETs) but clinical-molecular correlations have not been elucidated yet.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Aura Dulcinea Herrera-Martínez
#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump